Strongly coupled versus uncoupled spin response to radio frequency interference effects: application to glutamate and glutamine in spectroscopic imaging

Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker

Proton magnetic resonance spectroscopy (¹H-MRS) offers a growing variety of methods for querying potential diagnostic biomarkers of multiple sclerosis in living central nervous system tissue. For the past three decades, ¹H-MRS has enabled the acquisition of a rich dataset suggestive of numerous metabolic alterations in lesions, normal-appearing white matter, gray matter, and spinal cord of individuals with multiple sclerosis, but this body of information is not free of seeming internal contradiction. The use of ¹H-MRS signals as diagnostic biomarkers depends on reproducible and generalizable sensitivity and specificity to disease state that can be confounded by a multitude of influences, including experiment group classification and demographics; acquisition sequence; spectral quality and quantifiability; the contribution of macromolecules and lipids to the spectroscopic baseline; spectral quantification pipeline; voxel tissue and lesion composition; T₁ and T₂ relaxation; B₁ field characteristics; and other features of study design, spectral acquisition and processing, and metabolite quantification about which the experimenter may possess imperfect or incomplete information. The direct comparison of ¹H-MRS data from individuals with and without multiple sclerosis poses a special challenge in this regard, as several lines of evidence suggest that experimental cohorts may differ significantly in some of these parameters. We review the existing findings of in vivo¹H-MRS on central nervous system metabolic abnormalities in multiple sclerosis and its subtypes within the context of study design, spectral acquisition and processing, and metabolite quantification and offer an outlook on technical considerations, including the growing use of machine learning, by future investigations into diagnostic biomarkers of multiple sclerosis measurable by ¹H-MRS.

Measurement of N-acetylaspartylglutamate in the human frontal brain by 1H-MRS at 7 T

N-Acetylaspartylglutamate in human brain has been measured with difference editing at 7 T. The CH(2) proton resonances (∼ 2.5 ppm) of the aspartyl groups of N-acetylaspartylglutamate and N-acetylaspartate were difference edited (MEGA) using 20-msec gaussian radiofrequency pulses for selective 180 ° rotations of the coupling partners at 4.61 and 4.38 ppm, respectively. The echo time of the editing sequence, 108 msec, was obtained in phantom tests. Single-voxel localized in vivo measurements were conducted in the medial prefrontal and right frontal cortices of five healthy volunteers. The gray and white matter fractions within the voxels were obtained from T(1)-weighted image segmentation. Using linear regression of the metabolite concentration vs. fractional white matter contents within the voxels, the N-acetylaspartylglutamate-to-N-acetylaspartate concentration ratios in gray and white matter were estimated to be 0.13 and 0.28 by difference editing (95% confidence intervals 0.07-0.19 and 0.22-0.34), respectively, assuming identical relaxation effects between the metabolites.

Direct in vivo measurement of glycine and the neurochemical profile in the rat medulla oblongata

The medulla oblongata (MO) contains a high density of glycinergic synapses and a particularly high concentration of glycine. The aims of this study were to measure directly in vivo the neurochemical profile, including glycine, in MO using a spin-echo-based (1)H MRS sequence at TE = 2.8 ms and to compare it with three other brain regions (cortex, striatum and hippocampus) in the rat. Glycine was quantified in MO at TE = 2.8 ms with a Cramér-Rao lower bound (CRLB) of approximately 5%. As a result of the relatively low level of glycine in the other three regions, the measurement of glycine was performed at TE = 20 ms, which provides a favorable J-modulation of overlapping myo-inositol resonance. The other 14 metabolites composing the neurochemical profile were quantified in vivo in MO with CRLBs below 25%. Absolute concentrations of metabolites in MO, such as glutamate, glutamine, γ-aminobutyrate, taurine and glycine, were in the range of previous in vitro quantifications in tissue extracts. Compared with the other regions, MO had a three-fold higher glycine concentration, and was characterised by reduced (p < 0.001) concentrations of glutamate (-50 ± 4%), glutamine (-54 ± 3%) and taurine (-78 ± 3%). This study suggests that the functional specialisation of distinct brain regions is reflected in the neurochemical profile.

Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7T

An optimization of the PRESS sequence for magnetic resonance spectroscopy is presented to simultaneously detect the important brain metabolites of glutamate (Glu) and glutamine (Gln) at field strengths of 1.5, 3, 4.7, and 7T. Standard, clinical examinations typically use short echo times which in general are not ideal for the separation of Glu and Gln. The optimization procedure is based on numerical product operator simulations to produce yield and overlap measurements for all possible practical choices of PRESS inter-echo timings. The simulations illustrate the substantial modulations in Glu and Gln with field strength. At all field strengths, the optimized timings demonstrate a significant reduction in overlap compared to short echo PRESS, while maintaining a high metabolite signal, with Glu and Gln yields >90% when excluding T2 relaxation losses. Minimal overlap was attained at 7T (0.3% Gln contamination in the Glu signal), and 4.7T (1.2%). The optimized timings were applied in vivo on healthy volunteers at field strengths of 1.5 and 4.7T.